Latest Whitepapers

Download this whitepaper to discover how a contract development manufacturing organization was able to establish an AAV production platform and much more.

The battle against COVID-19 only begins with a test to identify who is infected and who is not. To accelerate an effective response, we have to move beyond the initial diagnosis to prognosis: Who is most susceptible to developing serious, life-threatening symptoms?

Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.

The choice of whether to outsource production of an in vitro diagnostic (IVD) or invest and develop inhouse capabilities is a foundational business decision. Capacity, capabilities and resources must all be assessed to determine the best course of action.

Download this whitepaper to discover a system that enhances sensitivity and maintains high resolution, fast scan speed as well as a wide dynamic range.

Antibody and other protein therapeutics are a major focus in drug discovery pipelines today. A critical stage in biologics drug discovery and development is the selection and characterization of lead molecules from large libraries.

Laboratory instruments are essential tools for reliable and efficient processing, whether that is liquid handling, storage, weighing or tube sorting. However, issues can arise with handling each new data stream that these instruments provide.

Download this whitepaper to learn more about balance requirements such as repeatability and minimum sample weight, equipment performance as well as use of internal test weights.

Download this whitepaper to learn more about mRNA therapeutics including how they could treat genetic diseases and cancer, the challenges associated with delivery and dosage as well as how to avoid an unwanted immune response.

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T-cell constructs to make them more effective, safe and persistent.